Peru has temporarily suspended clinical trials of a COVID vaccine made by Chinese drug giant Sinopharm after detecting neurological problems in one of its test volunteers.

The National Institute of Health said Friday that it had decided to interrupt the trial after a volunteer had difficulty moving their arms, according to local media.

"Several days ago we signaled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome," said chief researcher German Malaga in comments to the press.